In an interview to ET, he said the French company, which clocks annual revenue of about $8 billion, is looking at technologies like virtual twins to allow researchers to simulate human biology, develop personalised therapies and explore new ways to treat diseases with greater precision. Read The Rest at :
Disclaimer : Mymoneytimes implements extreme caution and care in collecting data before publication. Mymoneytimes does not liable for the adequacy, accuracy or completeness of any given information. Hence we are not liable for any kind of direct or indirect loss caused by the use of such information.
